Disease · HP_0000713
Trials93
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
1 to 20 of 93
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02446132 | Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | 1,197 | 2025-10-15 | Agitation in Patients With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02442778 | Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type | Phase 3 | 522 | 2022-09-09 | Agitation in Participants With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT01862640 | A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation | Phase 3 | 433 | 2020-06-16 | Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT03620981 | Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type | Phase 2/3 | 410 | 2024-11-14 | Agitation Associated With Dementia of the Alzheimer's Type | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02442765 | Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | 387 | 2023-02-13 | Agitation in Patients With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN HYDROBROMIDE, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT04276883 | Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder | Phase 3 | 380 | 2023-09-11 | Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00723606 | A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation | Phase 3 | 376 | 2010-08-25 | Schizophrenia | HALOPERIDOL, ZIPRASIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT00857649 | Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease | Phase 3 | 369 | 2012-01-09 | Alzheimer's Disease | MEMANTINE | Its record names the disease | ClinicalTrials.gov |
| NCT03226522 | Addressing Dementia Via Agitation-Centered Evaluation | Phase 2/3 | 366 | 2023-09-13 | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor | BUPROPION | Its record names the disease | ClinicalTrials.gov |
| NCT01735630 | Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease | Phase 2 | 350 | 2016-08-15 | Alzheimer's Disease | SCYLLITOL | Its record names the disease | ClinicalTrials.gov |
| NCT03548584 | A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type | Phase 3 | 345 | 2023-09-18 | Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT00628589 | Staccato Loxapine in Agitated Patients With Schizophrenia | Phase 3 | 344 | 2017-06-29 | Patients With Schizophrenia and Acute Agitation | LOXAPINE | Its record names the disease | ClinicalTrials.gov |
| NCT01922258 | Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type | Phase 3 | 270 | 2020-07-07 | Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT03594123 | A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type | Phase 3 | 259 | 2023-11-14 | Alzheimer's Disease | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT04464564 | Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | 241 | 2025-05-30 | Agitation in Patients With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN HYDROBROMIDE, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT01584440 | Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease | Phase 2 | 220 | 2021-11-26 | Agitation, Alzheimer's Disease | DEXTROMETHORPHAN, QUINIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00898807 | Citalopram for Agitation in Alzheimer's Disease | Phase 3 | 186 | 2014-06-27 | Alzheimer's Disease, Agitation | CITALOPRAM | Its record names the disease | ClinicalTrials.gov |
| NCT04408755 | Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | 184 | 2025-05-30 | Agitation in Patients With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN HYDROBROMIDE, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02035553 | A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis | Phase 2 | 181 | 2017-10-25 | Alzheimer's Disease Psychosis | PIMAVANSERIN | Its record names the disease | ClinicalTrials.gov |
| NCT02817906 | ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease | Phase 3 | 177 | 2021-06-29 | Agitation in Dementia, Including Alzheimer's Disease | LUMATEPERONE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000713/trials